cas 2637450-04-3|| where to buy methyl 4-((tert-butoxycarbonyl)(prop-2-yn-1-yl)amino)-3-methoxybenzoate

Nom du produit:methyl 4-((tert-butoxycarbonyl)(prop-2-yn-1-yl)amino)-3-methoxybenzoate

IUPAC Name:methyl 4-{[(tert-butoxy)carbonyl](prop-2-yn-1-yl)amino}-3-methoxybenzoate

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM362138-5g	4-6 Weeks	ȯȐȡȐ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2637450-04-3 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:2637450-04-3; Formule moléculaire:C17H21NO5; Point de fusion:-; Code SMILES:O=C(OC)C1=CC=C(N(C(OC(C)(C)C)=O)CC#C)C(OC)=C1; Densité:

: Numéro de catalogue:CM362138; Poids moléculaire:319.36; Point d'ébullition:; N° Mdl:; Stockage:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Rezatapopt; PMV Pharmaceuticals announced the latest results from a Phase 1/2 clinical trial of its potential first-in-class small molecule p53 reactivator rezatapopt (PC14586) for the treatment of patients with solid tumors. This candidate therapy is designed to selectively bind to the pocket of the TP53 Y220C mutant protein, thereby restoring wild-type or normal p53 protein structure and inhibiting tumor function. Previously, the US FDA granted PC14586 Fast Track designation for the treatment of patients with locally advanced or metastatic solid tumors carrying TP53 Y220C mutants.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.